Chronic kidney disease growth factors in renal fibrosis
- PMID: 21276040
- DOI: 10.1111/j.1440-1681.2011.05487.x
Chronic kidney disease growth factors in renal fibrosis
Abstract
1. The common pathological alteration in virtually every progressive chronic kidney disease (CKD) is renal fibrosis. 2. This review focuses on some growth factors, which are particularly well-established in contributing to fibrosis, such as the profibrotic, transforming growth factor-β, and connective tissue growth factor (CTGF), as well as the antifibrotic, bone morphogenic protein 7. The role of other growth factors is only starting to emerge (e.g. platelet-derived growth factor), and the role of yet others remains unclear (e.g. vascular endothelial growth factor). 3. Whether circulating or excreted, growth factors might serve as biomarkers of renal fibrosis and CKD remains largely unanswered. 4. Animal studies suggest that manipulation of growth factors might be an effective treatment option for patients with renal fibrosis and CKD. So far, only inhibition of CTGF is being tested in patients with diabetic nephropathy.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.
Similar articles
-
Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.FASEB J. 2003 Feb;17(2):268-70. doi: 10.1096/fj.02-0442fje. Epub 2002 Dec 3. FASEB J. 2003. PMID: 12475893
-
Transforming growth factor-beta/connective tissue growth factor axis in the kidney.Int J Biochem Cell Biol. 2008;40(1):9-13. doi: 10.1016/j.biocel.2007.01.006. Epub 2007 Jan 20. Int J Biochem Cell Biol. 2008. PMID: 17300978 Review.
-
Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.J Am Soc Nephrol. 2005 Jan;16(1):133-43. doi: 10.1681/ASN.2004040339. Epub 2004 Dec 1. J Am Soc Nephrol. 2005. PMID: 15574513
-
Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions.Am J Kidney Dis. 2010 Jun;55(6):1040-9. doi: 10.1053/j.ajkd.2010.01.021. Epub 2010 Apr 28. Am J Kidney Dis. 2010. PMID: 20430497
-
Progression in chronic kidney disease.Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65. doi: 10.1053/j.ackd.2005.07.011. Adv Chronic Kidney Dis. 2005. PMID: 16198274 Review.
Cited by
-
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.J Pharmacol Sci. 2012;119(2):131-8. doi: 10.1254/jphs.12031fp. Epub 2012 May 22. J Pharmacol Sci. 2012. PMID: 22673148 Free PMC article.
-
A functional MMP-9-1562C>T polymorphism, MMP-9 serum levels and nephrolithiasis risk in a southern Chinese population.Front Med (Lausanne). 2023 Jun 2;10:1175798. doi: 10.3389/fmed.2023.1175798. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37332754 Free PMC article.
-
Sinomenine Hydrochloride Attenuates Renal Fibrosis by Inhibiting Excessive Autophagy Induced by Adriamycin: An Experimental Study.Evid Based Complement Alternat Med. 2017;2017:6878795. doi: 10.1155/2017/6878795. Epub 2017 Jul 17. Evid Based Complement Alternat Med. 2017. PMID: 28798804 Free PMC article.
-
Interleukin-18 in Inflammatory Kidney Disease.Front Med (Lausanne). 2021 Mar 1;8:639103. doi: 10.3389/fmed.2021.639103. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33732720 Free PMC article. Review.
-
Nano-sized carriers in gene therapy for renal fibrosis in vivo.Nano Rev Exp. 2017 Jun 13;8(1):1331099. doi: 10.1080/20022727.2017.1331099. eCollection 2017. Nano Rev Exp. 2017. PMID: 30410705 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous